IN8bio, Inc. Share Price & Technical Analysis
INAB · $1.67 (-0.60%)
Healthcare / Biotechnology
$1.67
-0.60%
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
13% return in May, 37% avg return in past 3 year May month.
-22% return in 2026, -60% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -13% | -11% | -12% | 0% | 13% | – | – | – | – | – | – | – | -22% |
| 25 | -3% | 13% | -40% | 2% | -15% | -47% | 0% | 5% | 0% | -5% | 0% | 15% | -76% |
| 24 | -5% | -15% | 4% | -13% | 17% | -31% | -1% | -36% | -48% | 4% | 8% | -17% | -132% |
| 23 | 3% | -35% | -14% | 5% | 111% | -49% | -27% | -12% | -2% | -4% | -11% | 62% | 28% |
| 22 | -23% | 28% | -21% | -31% | -12% | -4% | 14% | 9% | -20% | -2% | -10% | 37% | -33% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$15.76M
P/E ratio
—
52W high
$5.61
52W low
$1.17
Volume
87,649
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is IN8bio, Inc. share price today?
- IN8bio, Inc. (INAB) last traded around $1.67 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INAB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INAB. Download the app for real-time alerts.
- How can I analyze IN8bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.